Cited by 393Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment ResearchSleep and related disorders

Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder

Open access
Boeve, B.F., Silber, M.H., Ferman, T.J., Lin, S.C., Benarroch, E.E., Schmeichel, A.M., Ahlskog, J.E., Caselli, R.J. +23 more·2013·Sleep Medicine

Abstract

Objective To determine the pathologic substrates in patients with rapid eye movement (REM) sleep behavior disorder (RBD) with or without a coexisting neurologic disorder.Methods The clinical and neuropathologic findings were analyzed on all autopsied cases from one of the collaborating sites in North America and Europe, were evaluated from January 1990 to March 2012, and were diagnosed with polysomnogram (PSG)-proven or probable RBD with or without a coexisting neurologic disorder. The clinical and neuropathologic diagnoses were based on published criteria.Results 172 cases were identified, of whom 143 (83%) were men. The mean±SD age of onset in years for the core features were as follows - RBD, 62±14 (range, 20-93), cognitive impairment (n=147); 69±10 (range, 22-90), parkinsonism (n=151); 68±9 (range, 20-92), and autonomic dysfunction (n=42); 62±12 (range, 23-81). Death age was 75±9 years (range, 24-96). Eighty-two (48%) had RBD confirmed by PSG, 64 (37%) had a classic history of recurrent dream enactment behavior, and 26 (15%) screened positive for RBD by questionnaire. RBD preceded the onset of cognitive impairment, parkinsonism, or autonomic dysfunction in 87 (51%) patients by 10±12 (range, 1-61) years. The primary clinical diagnoses among those with a coexisting neurologic disorder were dementia with Lewy bodies (n=97), Parkinson's disease with or without mild cognitive impairment or dementia (n=32), multiple system atrophy (MSA) (n=19), Alzheimer's disease (AD)(n=9) and other various disorders including secondary narcolepsy (n=2) and neurodegeneration with brain iron accumulation-type 1 (NBAI-1) (n=1). The neuropathologic diagnoses were Lewy body disease (LBD)(n=77, including 1 case with a duplication in the gene encoding α-synuclein), combined LBD and AD (n=59), MSA (n=19), AD (n=6), progressive supranulear palsy (PSP) (n=2), other mixed neurodegenerative pathologies (n=6), NBIA-1/LBD/tauopathy (n=1), and hypothalamic structural lesions (n=2). Among the neurodegenerative disorders associated with RBD (n=170), 160 (94%) were synucleinopathies. The RBD-synucleinopathy association was particularly high when RBD preceded the onset of other neurodegenerative syndrome features.Conclusions In this large series of PSG-confirmed and probable RBD cases that underwent autopsy, the strong association of RBD with the synucleinopathies was further substantiated and a wider spectrum of disorders which can underlie RBD now are more apparent.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.sleep.2012.10.015

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There are still no direct biomarkers to establish dementia with Lewy bodies, but indicative biomarkers include reduced dopamine transporter uptake on SPECT or PET, reduced MIBG myocardial scintigraphy uptake, and polysomnographic confirmation of REM sleep without atonia.

    “While there are still no direct biomarkers to establish dementia with Lewy bodies, indicative biomarkers include reduced dopamine transporter (DAT) uptake in the basal ganglia on single photon emission computerized tomography (SPECT) or PET imaging165, 166, reduced iodine‐metaiodobenzylguanidine (MIBG) myocardial scintigraphy uptake 165 , and polysomnographic confirmation of REM sleep without at”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Boeve, B. F., Silber, M. H., Ferman, T. J., Lin, S. C., Benarroch, E. E., Schmeichel, A. M., Ahlskog, J. E., Caselli, R. J., Jacobson, S., Sabbagh, M., Adler, C., Woodruff, B., Beach, T. G., Iranzo, A., Gelpi, E., Santamaria, J., Tolosa, E., Singer, C., Mash, D. C., Luca, C., Arnulf, I., Duyckaerts, C., Schenck, C. H., Mahowald, M. W., Dauvilliers, Y., Graff-Radford, N. R., Wszolek, Z. K., Parisi, J. E., Dugger, B., Murray, M. E., & Dickson, D. W.
Affiliations
  • Mayo Clinic (US)
  • Banner Sun Health Research Institute (US)
  • Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
  • University of Miami (US)
  • Inserm (FR)
  • University of Minnesota (US)
  • Centre Hospitalier Universitaire de Montpellier (FR)
Corresponding author
Boeve, B.F.
Venue
Sleep Medicine
Publisher
Elsevier BV
Published
2013-08
Volume
14
Issue
8
Pages
754-762
ISSN
1389-9457 (ISSN-L)
OpenAlex
W2097714090
Cited by
393
References
119
Citations by year
2026: 12 · 2025: 22 · 2024: 25 · 2023: 27 · 2022: 37 · 2021: 30 · 2020: 31 · 2019: 37 · 2018: 38 · 2017: 36 · 2016: 39 · 2015: 26 · 2014: 21 · 2013: 10 · 2012: 1
FWCI
20.30
Type
journal article
Language
en
Open access
Locations
  • Sleep Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Academy of Neurology
  • National Institute on Aging (R01AG015866, AG016574, AG-19610, U01AG006786, AG015866, AG-006786, P30AG019610, P50AG016574)
  • National Institute of Neurological Disorders and Stroke (U24NS072026, P50NS072187)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
Keywords
rapid eye movement sleep behavior disorder, clinicopathological correlation, neuropathology, Lewy body disease, dementia with Lewy bodies, Parkinson's disease, multiple system atrophy, Alzheimer's disease, autonomic dysfunction, parkinsonism, cognitive impairment, alpha-synuclein, brain iron accumulation, neurodegeneration, dream enactment behavior, age of onset, disease progression
MeSH terms
Adult, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Middle Aged, Narcolepsy, Parkinson Disease, Supranuclear Palsy, Progressive, Age of Onset, Multiple System Atrophy, REM Sleep Behavior Disorder, Lewy Body Disease, Young Adult, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review